Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$21.48
+0.8%		$20.02
$13.46
▼
$31.04
$586.08M0.93315,862 shs297,613 shs
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
$25.99
+0.9%		$26.40
$15.69
▼
$27.94
$2.09B0.61730,383 shs616,413 shs
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$18.47
+3.9%		$17.27
$7.07
▼
$20.05
$2.28B1.792.00 million shs2.30 million shs
GeneDx Holdings Corp. stock logo
WGS
GeneDx
$73.09
+3.0%		$81.80
$32.21
▼
$170.87
$2.18B1.95754,176 shs606,670 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
+0.85%-3.24%+7.19%+3.02%-8.60%
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
+0.78%-1.12%-3.17%-2.50%+53.14%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
+3.88%-4.45%+6.15%+21.83%+111.81%
GeneDx Holdings Corp. stock logo
WGS
GeneDx
+3.00%-17.32%-15.72%+8.27%-35.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$21.48
+0.8%		$20.02
$13.46
▼
$31.04
$586.08M0.93315,862 shs297,613 shs
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
$25.99
+0.9%		$26.40
$15.69
▼
$27.94
$2.09B0.61730,383 shs616,413 shs
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$18.47
+3.9%		$17.27
$7.07
▼
$20.05
$2.28B1.792.00 million shs2.30 million shs
GeneDx Holdings Corp. stock logo
WGS
GeneDx
$73.09
+3.0%		$81.80
$32.21
▼
$170.87
$2.18B1.95754,176 shs606,670 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
+0.85%-3.24%+7.19%+3.02%-8.60%
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
+0.78%-1.12%-3.17%-2.50%+53.14%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
+3.88%-4.45%+6.15%+21.83%+111.81%
GeneDx Holdings Corp. stock logo
WGS
GeneDx
+3.00%-17.32%-15.72%+8.27%-35.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
2.00
Hold$27.5028.03% Upside
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
2.17
Hold$26.602.34% Upside
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2.50
Moderate Buy$17.67-4.35% Downside
GeneDx Holdings Corp. stock logo
WGS
GeneDx
2.89
Moderate Buy$90.8624.31% Upside

Current Analyst Ratings Breakdown

Latest FLGT, NEO, WGS, and MD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/1/2026
GeneDx Holdings Corp. stock logo
WGS
GeneDx
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$74.00 ➝ $83.00
9/28/2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/9/2026
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
8/27/2026
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/26/2026
GeneDx Holdings Corp. stock logo
WGS
GeneDx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/25/2026
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
8/19/2026
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$27.00 ➝ $28.00
8/6/2026
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$25.00 ➝ $28.00
8/5/2026
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold$25.00
8/4/2026
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
8/4/2026
GeneDx Holdings Corp. stock logo
WGS
GeneDx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D)
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$322.67M1.83N/AN/A$35.80 per share0.60
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
$1.91B1.10$2.26 per share11.52$10.08 per share2.58
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$727.33M3.26$0.35 per share53.07$6.47 per share2.85
GeneDx Holdings Corp. stock logo
WGS
GeneDx
$427.54M5.10$2.36 per share30.96$10.54 per share6.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$60.51M-$2.82N/AN/AN/A-26.05%-4.93%-4.50%11/6/2026 (Estimated)
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
$165.39M$2.0912.4411.66N/A8.96%20.05%8.15%11/2/2026 (Estimated)
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$108.03M-$0.40N/A369.40N/A-6.77%-1.99%-1.21%10/27/2026 (Estimated)
GeneDx Holdings Corp. stock logo
WGS
GeneDx
-$21.02M-$3.64N/A63.56N/A-23.41%4.12%2.26%10/27/2026 (Estimated)

Latest FLGT, NEO, WGS, and MD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/27/2026Q3 2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$0.06N/AN/AN/A$205.89 millionN/A
10/27/2026Q3 2026
GeneDx Holdings Corp. stock logo
WGS
GeneDx
$0.07N/AN/AN/A$122.93 millionN/A
8/4/2026Q2 2026
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
$0.5910$0.63+$0.0390$0.49$478.49 million$487.78 million
8/3/2026Q2 2026
GeneDx Holdings Corp. stock logo
WGS
GeneDx
-$0.1879$0.01+$0.1979-$0.60$111.01 million$114.44 million
7/30/2026Q2 2026
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$0.46-$0.58-$0.12-$1.05$94.00 million$85.39 million
7/28/2026Q2 2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$0.0336$0.05+$0.0165$0.02$196.93 million$201.66 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/AN/AN/AN/AN/A
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
N/AN/AN/AN/AN/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
N/AN/AN/AN/AN/A
GeneDx Holdings Corp. stock logo
WGS
GeneDx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/A
6.34
6.34
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
0.45
1.32
1.32
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
0.48
3.60
3.35
GeneDx Holdings Corp. stock logo
WGS
GeneDx
0.40
3.30
3.06

Institutional Ownership

CompanyInstitutional Ownership
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
48.06%
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
97.71%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
98.50%
GeneDx Holdings Corp. stock logo
WGS
GeneDx
61.72%

Insider Ownership

CompanyInsider Ownership
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
36.18%
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
1.80%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
1.10%
GeneDx Holdings Corp. stock logo
WGS
GeneDx
25.17%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
1,31527.51 million17.56 millionOptionable
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
4,31581.25 million79.79 millionOptionable
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2,500128.48 million127.06 millionOptionable
GeneDx Holdings Corp. stock logo
WGS
GeneDx
1,30029.82 million22.32 millionOptionable

Recent News About These Companies

Guggenheim Forecasts Strong Price Appreciation for GeneDx (NASDAQ:WGS) Stock
October 3 at 2:36 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081780
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
October 2 at 8:30 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261001771109/en/genedx-introduces-easy-order-at-aap-2026-to-simplify-genomic-testing-in-everyday-pediatric-care/
GeneDx (NASDAQ:WGS) Stock Price Expected to Rise, Guggenheim Analyst Says
October 1 at 9:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-genedx-nasdaq-wgs-stock-price-expected-to-rise-guggenheim-analyst-says-2026-10-01/
GeneDx (NASDAQ:WGS) Shares Down 5.9% - Should You Sell?
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-genedx-nasdaq-wgs-shares-down-59-should-you-sell-2026-09-29/
GeneDx Stock Is Down 30% In Last 1 Year, Can It Climb Again in 2027?
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/genedx-stock-down-30-last-133314557.html
GeneDx (NASDAQ:WGS) Stock Price Up 7.9% - Here's Why
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-genedx-nasdaq-wgs-stock-price-up-79-heres-why-2026-09-24/
GeneDx (NASDAQ:WGS) Trading Down 6.5% - Time to Sell?
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044459
GeneDx (NASDAQ:WGS) Stock Price Down 6.5% - Here's Why
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-genedx-nasdaq-wgs-stock-price-down-65-heres-why-2026-09-22/
Corient Private Wealth LP Makes New $3.07 Million Investment in GeneDx Holdings Corp. $WGS
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-makes-new-307-million-investment-in-genedx-holdings-corp-wgs-2026-09-21/
GeneDx (NASDAQ:WGS) CFO Sells $363,890.08 in Stock
September 19, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-wgs-insider-buying-and-selling-2026-09-19/
Insider Selling: GeneDx (NASDAQ:WGS) CFO Sells $363,890.08 in Stock
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-genedx-nasdaq-wgs-cfo-sells-36389008-in-stock-2026-09-18/
GeneDx (NASDAQ:WGS) CEO Sells $1,025,002.61 in Stock
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-genedx-nasdaq-wgs-ceo-sells-102500261-in-stock-2026-09-18/
GeneDx Holdings Corp. (NASDAQ:WGS) Receives Consensus Rating of "Moderate Buy" from Analysts
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-genedx-holdings-corp-nasdaq-wgs-receives-consensus-rating-of-moderate-buy-from-analysts-2026-09-16/
GeneDx (NASDAQ:WGS) Trading Up 4.2% - What's Next?
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-genedx-nasdaq-wgs-trading-up-42-whats-next-2026-09-15/
How Genedx Holdings Corp. (WGS) Affects Rotational Strategy Timing
September 14, 2026  |  news.stocktradersdaily.comN
GeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 1,285 Shares of Stock
September 12, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-wgs-insider-buying-and-selling-2026-09-12/
Kevin Feeley Sells 1,285 Shares of GeneDx (NASDAQ:WGS) Stock
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-kevin-feeley-sells-1285-shares-of-genedx-nasdaq-wgs-stock-2026-09-11/
GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 3,692 Shares of Stock
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-genedx-nasdaq-wgs-ceo-katherine-stueland-sells-3692-shares-of-stock-2026-09-11/
First Light Asset Management LLC Has $53.82 Million Position in GeneDx Holdings Corp. $WGS
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-first-light-asset-management-llc-has-5382-million-position-in-genedx-holdings-corp-wgs-2026-09-10/
3 Promising Genomics Stocks in the Spotlight in 2026
September 8, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2986615/3-promising-genomics-stocks-in-the-spotlight-in-2026?cid=cs-stocknewsapi-ft-genomics_&_synthetic_biology-2986615
Bank of New York Mellon Corp Invests $4.26 Million in GeneDx Holdings Corp. $WGS
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-invests-426-million-in-genedx-holdings-corp-wgs-2026-09-06/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Server racks with blue lighting in a data center, with a candlestick stock price chart displayed on a monitor.
Short Sellers Are Betting Against 3 AI Infrastructure Stocks—What Could Turn the Tide?
By Leo Miller | September 8, 2026
Stacked gold bars on a desk in front of a computer screen displaying an upward-trending bar chart.
This Gold ETF Turns a Non-Yielding Asset Into Monthly Income—But There’s a Catch
By Jessica Mitacek | September 17, 2026
Office desk with a monitor displaying video, audio, and facial recognition data analysis alongside a lit Veritone logo on the wall.
Think Outside the Box With These 3 Companies That Make Unusual Business Models Work
By Nathan Reiff | September 21, 2026
CoreWeave logo displayed in a data center aisle lined with server racks and digital network graphics.
CoreWeave Comes With Risks: Analysts Split on What Matters Most
By Chris Markoch | September 29, 2026
Nasdaq logo above a large screen displaying an upward-trending stock price chart in the Times Square studio.
The Nasdaq Nears a Major Breakout: 5 Tech ETFs to Play the Move
By Ryan Hasson | September 28, 2026
Fulgent Genetics stock logo

Fulgent Genetics NASDAQ:FLGT

$21.48 +0.18 (+0.85%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$21.43 -0.05 (-0.23%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Pediatrix Medical Group stock logo

Pediatrix Medical Group NYSE:MD

$25.99 +0.23 (+0.90%)
Closing price 10/2/2026 03:59 PM Eastern
Extended Trading
$26.00 +0.00 (+0.01%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals, including pediatric nurse practitioners, echocardiographers, other diagnostic technicians, and exercise physiologists; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians, pediatric gastroenterologists; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

NeoGenomics stock logo

NeoGenomics NASDAQ:NEO

$18.47 +0.69 (+3.88%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$18.51 +0.04 (+0.20%)
As of 10/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

GeneDx stock logo

GeneDx NASDAQ:WGS

$73.09 +2.13 (+3.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$72.42 -0.67 (-0.91%)
As of 10/2/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas